Steven R. Steinhubl - Concepedia

Author

Steven R. Steinhubl

Also Known As

S STEINHUBL, S Steinhubl, S. R Steinhubl, S. R. Steinhubl, S.R. STEINHUBL, S.R. Steinhubl, STEVEN R. STEINHUBL, Steven R Steinhubl, Steven R. Steinhubl, Steven Steinhubl

175

Publications

15.2K

Citations

H-Index

Concepts

All Affiliations

University of Kentucky Cleveland Clinic Geisinger Medical Center Sorbonne Université Scripps Clinic

About

Steven R. Steinhubl is an author at University of Kentucky specializing in medicine, cardiovascular disease, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	32	4.3K
2	Emergency Medicine	11	11	953
3	Health Sciences	4	4	252
4	Public Health	3	3	217
5	Biomedical Engineering	1	1	26

Steven R. Steinhubl

Publications

12.1K

Citations

H-Index

Page 1

	Year	Citations
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention Steven R. Steinhubl, Peter B. Berger, J. Tift Mann, JAMA	2002	3.1K
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events Deepak L. Bhatt, Keith A.A. Fox, Werner Hacke, New England Journal of Medicine	2006	2.8K
Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial Deepak L. Bhatt, Marcus Flather, Werner Hacke, Journal of the American College of Cardiology Charisma TrialCardiovascular DiseasePrior Myocardial InfarctionMedicineArterial Disease Treatment	2007	799
Variability in platelet responsiveness to clopidogrel among 544 individuals Victor L. Serebruany, Steven R. Steinhubl, Peter B. Berger, Journal of the American College of Cardiology ThrombopoiesisThrombosisCardiovascular DiseaseBlood PlateletHematology	2005	776
Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial Jacqueline Saw, Steven R. Steinhubl, Peter B. Berger, Circulation	2003	266
Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease Peter B. Berger, Deepak L. Bhatt, Valentı́n Fuster, Circulation	2010	230
Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid John W. Eikelboom, Graeme J. Hankey, Jim Thom, Circulation	2008	228
First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology Christopher K. Dyke, Steven R. Steinhubl, Neal S. Kleiman, Circulation	2006	218
Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention Steven R. Steinhubl, Peter B. Berger, Danielle M. Brennan, Journal of the American College of Cardiology ThrombosisPercutaneous Coronary InterventionOptimal TimingCardiovascular DiseaseCoronary Unit	2006	198
Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery Jeffrey S. Berger, Carla B. Frye, Qing Harshaw, Journal of the American College of Cardiology ThrombosisCardiorenal SyndromesCardiovascular DiseaseCoronary Artery DiseaseVascular Surgery	2008	196

Page 1